A Multicentre, Randomized, Double-Blind, Active and Placebo-Controlled Study of Pecavaptan, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients with Acute Heart Failure: The AVANTI Trial

Authors

Nicolas Girerd (ORCID: https://orcid.org/0000-0002-3278-2057)
Finn Gustafsson (ORCID: https://orcid.org/0000-0003-2144-341X)
Gerald Staedtler
Pablo C. Colorado (ORCID: https://orcid.org/0009-0005-4228-7366)
Kévin Duarte (ORCID: https://orcid.org/0000-0002-0292-0498)
Daniel Burkhoff (ORCID: https://orcid.org/0000-0003-3995-2466)
Peter Kolkhof (ORCID: https://orcid.org/0000-0003-3425-7528)
Iouri Bachmakov (ORCID: https://orcid.org/0009-0004-0039-6401)
Luca Monzo (ORCID: https://orcid.org/0000-0003-2958-943X)
James E. Udelson (ORCID: https://orcid.org/0000-0003-2998-910X)
Wilfried Dinh (ORCID: https://orcid.org/0000-0001-9929-4253)
Adriaan A. Voors
Steven R. Goldsmith
Faiez Zannad

Institutions

University of Copenhagen (DK)
Tufts Medical Center (US)
University of Minnesota (US)
University Medical Center Groningen (NL)
Bayer (United States) (US)
Inserm (FR)
Witten/Herdecke University (DE)
University of Groningen (NL)
Hennepin County Medical Center (US)
Copenhagen University Hospital (DK)
Rigshospitalet (DK)
Cardiovascular Research Foundation (US)
Bayer (Germany) (DE)
Université de Lorraine (FR)

Publication Details

Journal: European Journal of Heart Failure
Published: 2025-08-11
DOI: https://doi.org/10.1002/ejhf.3801
Citations: 2
Primary Topic: Electrolyte and hormonal disorders
Type: article
Field-Weighted Citation Impact: 3.04

Funders

Bayer

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

A Multicentre, Randomized, Double-Blind, Active and Placebo-Controlled Study of Pecavaptan, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients with Acute Heart Failure: The AVANTI Trial

Nicolas Girerd, Finn Gustafsson, Gerald Staedtler, Pablo C. Colorado et al.

Aug 11, 2025

2 citations

European Journal of Heart Failure

Electrolyte and hormonal disorders

3.04

article

A Multicentre, Randomized, Double-Blind, Active and Placebo-Controlled Study of Pecavaptan, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients with Acute Heart Failure: The AVANTI Trial

Nicolas Girerd, Finn Gustafsson, Gerald Staedtler, Pablo C. Colorado, Kévin Duarte, Daniel Burkhoff, Peter Kolkhof, Iouri Bachmakov, Luca Monzo, James E. Udelson, Wilfried Dinh, Adriaan A. Voors, Steven R. Goldsmith, Faiez Zannad

August 11, 2025article en

2 citations

Abstract

No abstract available for this paper.

European Journal of Heart FailureVol. 27(11)

University of Copenhagen (DK), Tufts Medical Center (US), University of Minnesota (US), University Medical Center Groningen (NL), Bayer (United States) (US), Inserm (FR), Witten/Herdecke University (DE), University of Groningen (NL), Hennepin County Medical Center (US), Copenhagen University Hospital (DK), Rigshospitalet (DK), Cardiovascular Research Foundation (US), Bayer (Germany) (DE), Université de Lorraine (FR)

Bayer

Good health and well-being

Openalex Percentile: Top 8%

Electrolyte and hormonal disorders

3.04

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A Multicentre, Randomized, Double-Blind, Active and Placebo-Controlled Study of Pecavaptan, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients with Acute Heart Failure: The AVANTI Trial — Nicolas Girerd, Finn Gustafsson, et al. · European Journal of Heart Failure (2025) | TGRS Research Map | TGRS